Squamous Cell Carcinoma of the Palatine Tonsils: FDG Standardized Uptake Value Ratio as a Biomarker to Differentiate Tonsillar Carcinoma from Physiologic Uptake

被引:48
作者
Davison, Jessica M. [1 ]
Ozonoff, Al [1 ]
Imsande, Heather M. [1 ]
Grillone, Gregory A. [1 ]
Subramaniam, Rathan M. [1 ]
机构
[1] Boston Univ, Sch Med, Dept Radiol, Boston, MA 02118 USA
关键词
POSITRON-EMISSION-TOMOGRAPHY; OCCULT PRIMARY TUMORS; NECK-CANCER; HEAD; PET; FLUORODEOXYGLUCOSE; F-18-FDG; IMPACT; CHEMOTHERAPY; RADIOTHERAPY;
D O I
10.1148/radiol.10091479
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Purpose: To quantify fluorine 18 (F-18) fluorodeoxyglucose (FDG) uptake in the palatine tonsils to identify a sensitive and specific metric for distinguishing physiologic asymmetric uptake from squamous cell carcinoma (SCC). Materials and Methods: This HIPAA-compliant retrospective study was approved by institutional review board. Informed consent requirements were waived. Twenty-six patients (seven female, 19 male; mean age, 53.46 years +/- 10.45 [standard deviation]) with tonsillar SCC were included. Twenty-six patients (seven female, 19 male; mean age, 61.77 years +/- 10.12) with head and neck carcinomas not involving the tonsils were included as control subjects. Tonsil standardized uptake values (SUVs) were measured bilaterally in each group. Independent-samples t test was used to compare mean SUVs, and Pearson correlation was used to evaluate association of FDG uptake between tonsils within control subjects. Results: The mean maximum SUV (SUVmax) of tonsil tumors was 9.36 +/- 4.54, which was significantly higher than that of contralateral cancer-free tonsils (2.54 +/- 0.88; P < .0001) and tonsils in control subjects (2.98 +/- 1.08; P < .0001). In patients with tonsillar cancer, the mean difference in SUVmax between tonsils was 10.43 +/- 7.07, which was significantly greater than that in control subjects (0.62 +/- 0.54; P < .0001). The mean SUVmax ratio between tonsils in patients with carcinoma was 3.79 +/- 1.69, which was threefold higher than in control subjects (1.18 +/- 0.13; P < .0001). For receiver operating characteristic analysis using SUVmax ratio to differentiate benign uptake from SCC, the area under the curve was 1.00 (95% confidence interval: 1.00, 1.00). A cutoff ratio of 1.48 had 100% sensitivity and specificity. Conclusion: The SUVmax ratio represents an accurate imaging biomarker for differentiating tonsillar SCC from physiologic F-18-FDG uptake. (C) RSNA, 2010
引用
收藏
页码:578 / 585
页数:8
相关论文
共 32 条
[1]   Metastatic head and neck cancer: Role and usefulness of FDG PET in locating occult primary tumors [J].
Aassar, OS ;
Fischbein, NJ ;
Caputo, GR ;
Kaplan, MJ ;
Price, DC ;
Singer, MI ;
Dillon, WP ;
Hawkins, RA .
RADIOLOGY, 1999, 210 (01) :177-181
[2]   Standardized uptake value of 2-[18F] fluoro-2-deoxy-D-glucose in predicting outcome in head and neck carcinomas treated by radiotherapy with or without chemotherapy [J].
Allal, AS ;
Dulguerov, P ;
Allaoua, M ;
Haenggeli, CA ;
El Ghazi, EA ;
Lehmann, W ;
Slosman, DO .
JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (05) :1398-1404
[3]  
Bakheet SM, 1998, SEMIN NUCL MED, V28, P352
[4]   Significance of incidental fluorodeoxyglucose uptake in the parotid glands and its impact on patient management [J].
Basu, Sandip ;
Houseni, Mohamed ;
Alavi, Abass .
NUCLEAR MEDICINE COMMUNICATIONS, 2008, 29 (04) :367-373
[5]  
Chen YK, 2007, J NUCL MED, V48, P8
[6]   Normal physiological and benign pathological variants of 18-fluoro-2-deoxyglucose positron-emission tomography scanning: Potential for error in interpretation [J].
Cook, GJR ;
Fogelman, I ;
Maisey, MN .
SEMINARS IN NUCLEAR MEDICINE, 1996, 26 (04) :308-314
[7]   Normal variants, artefacts and interpretative pitfalls in PET imaging with 18-fluoro-2-deoxyglucose and carbon-11 methionine [J].
Cook, GJR ;
Maisey, MN ;
Fogelman, I .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE, 1999, 26 (10) :1363-1378
[8]  
Duarte Paulo S, 2002, Mol Imaging Biol, V4, P157
[9]   Molecular Pathology in Vulnerable Carotid Plaques: Correlation with [18]-Fluorodeoxyglucose Positron Emission Tomography (FDG-PET) [J].
Graebe, M. ;
Pedersen, S. F. ;
Borgwardt, L. ;
Hojgaard, L. ;
Sillesen, H. ;
Kjaer, A. .
EUROPEAN JOURNAL OF VASCULAR AND ENDOVASCULAR SURGERY, 2009, 37 (06) :714-721
[10]  
Greven KM, 1999, CANCER, V86, P114, DOI 10.1002/(SICI)1097-0142(19990701)86:1<114::AID-CNCR16>3.0.CO